BioCryst's immune disorder drug succeeds in mid-stage trial

Send a link to a friend  Share

[May 27, 2014]  (Reuters) - BioCryst Pharmaceuticals Inc said its experimental drug to treat a rare immune disorder was found effective in reducing attacks related to the condition, in a mid-stage trial.

The company's stock jumped 21 percent to $10.90 in trading before the bell on Tuesday.

The oral drug, BCX4161, was being evaluated against a placebo in patients with hereditary angioedema (HAE) a genetic disease characterized by sudden attacks of swelling of the skin or the mucous membranes, which can be disfiguring, painful and life-threatening.

Those who received the drug had an average rate of 0.82 attacks per week, compared with 1.27 for those given a placebo, BioCryst said in a statement.

The study tested the safety and efficacy of a 400 mg dose of the drug administered three times a day for 28 days.

The patients given the drug went 22 days on average without an attack, compared with 19 days for those given the placebo, the drugmaker said.

BioCryst, which is also developing drugs for infectious diseases and gout, currently sells its influenza treatment Peramivir in Japan and Korea.

The Research Triangle Park, North Carolina-based company's shares closed at $9.005 on the Nasdaq on Friday.

[to top of second column]

(Reporting by Esha Dey and Natalie Grover in Bangalore; Editing by Savio D'Souza)

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

< Recent articles

Back to top